SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 19.58 |
| Enterprise Value ($M) | 1.25 |
| Book Value ($M) | 60.02 |
| Book Value / Share | 1.01 |
| Price / Book | 0.33 |
| NCAV ($M) | 59.12 |
| NCAV / Share | 1.00 |
| Price / NCAV | 0.33 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.49 |
| Return on Assets (ROA) | -0.41 |
| Return on Equity (ROE) | -0.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 21.21 |
| Current Ratio | 21.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 94.73 |
| Assets | 95.63 |
| Liabilities | 35.60 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -44.70 |
| Net Income | -44.48 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -36.36 |
| Cash from Investing | -8.37 |
| Cash from Financing | 44.94 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | BML Investment Partners, L.P. | 9.90 | 0.00 | |
| 13G/A | Logos Global Management LP | 0.00 | -100.00 | |
| 13G/A | Goldman Sachs Group Inc | 2.80 | -62.73 | |
| 13G/A | Farallon Capital Partners, L.P. | 6.00 | 0.00 | |
| 13G | BlackRock, Inc. | 5.40 | ||
| 13G/A | Vanguard Group Inc | 4.41 | -15.03 | |
| 13G/A | Orbimed Advisors Llc | 4.00 | -18.62 | |
| 13G/A | Point72 Asset Management, L.P. | 0.80 | -87.62 | |
| 13G/A | Biotechnology Value Fund L P | 9.99 | 39.99 | |
| 13G/A | Great Point Partners Llc | 0.00 | -100.00 | |
| 13G/A | Aisling Capital IV, LP | 4.92 | 1.21 | |
| 13G/A | Empery Asset Management, LP | 4.99 | 40.83 | |
| 13D/A | venBio Global Strategic Fund III, L.P. | 3.40 | -19.93 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 11.00 | 102.58 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 747,748 | 2,580,392 | 28.98 | |
| 1,099,763 | 3,183,684 | 34.54 | |
| 321,048 | 847,396 | 37.89 | |
| 248,779 | 570,964 | 43.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DYAI – Dyadic International, Inc. | EDSA – Edesa Biotech, Inc. |
| ELDN – Eledon Pharmaceuticals, Inc. | ELTX – Elicio Therapeutics, Inc. |
| ELUT – Elutia Inc. |
Financial data and stock pages provided by
Fintel.io